Ocular Therapeutix, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of Ocular Therapeutix, Inc. (NasdaqGM: OCUL) violated federal securities laws by issuing materially false and misleading statements regarding the company’s business and operations. Ocular, a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States.

Ocular Fails to Report Extent of Manufacturing Issues at Its Plant

On May 5, 2017, Ocular revealed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant. On July 6, 2017, Seeking Alpha reported that Ocular officials had been misleading investors about manufacturing issues and that the company failed to establish scientifically sound and appropriate test procedures for its drug products. The article further asserted that Ocular’s approach to patient safety is “highly questionable” and that over half of lots manufactured by Ocular contain bad product. On this news, Ocular’s stock fell over 30% to close at $7.12 per share on July 7, 2017, and has since fallen even further, closing at $6.38 per share on September 22, 2017.

Ocular Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003 or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post